Genmab A/S
AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT
Last updated:
Abstract:
The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
Status:
Application
Type:
Utility
Filling date:
3 Jun 2020
Issue date:
24 Dec 2020